Form 4: Ellen Chiniara Acquires 40,000 Stock Options in Compass Therapeutics

Director Ellen Chiniara acquired 40,000 stock options in Compass Therapeutics (CMPX) on February 11, 2025, according to a Form 4 filing.

Summary

• Ellen Chiniara, a Director of Compass Therapeutics, Inc. (CMPX), acquired 40,000 stock options on February 11, 2025.
• The options have an exercise price of $3.65.
• The options vest in 48 substantially equal monthly installments starting March 11, 2025.
• The options expire on February 11, 2035.
• Following the transaction, Chiniara directly owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of options could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates